...
首页> 外文期刊>International Journal of Hematology and Oncology >Albumin Infusion is not Beneficial in Hypoalbuminemic End-Stage Cancer Patients: A Matched-Pair Analysis
【24h】

Albumin Infusion is not Beneficial in Hypoalbuminemic End-Stage Cancer Patients: A Matched-Pair Analysis

机译:低蛋白血症晚期癌症患者的白蛋白输注不是有益的:配对分析

获取原文

摘要

In this retrospective study, it was aimed whether albumin infusion is benefical or not in terminally ill hospitalized hypoalbuminemic cancer patients. Between March 2000 and 31 March 2003, the medical records of 27 terminally ill hypoalbuminemic cancer patients who had albumin infusion(Albumin receiving group-ARG), were retrospectively analysed. This grup was matched (1:1) with 27 terminally ill cancer patients who had no albumin infusion (Albumin not receiving group-ANRG), according to age, sex, ECOG PS, diagnosis and the number of metastatic sites. ARG was compared with ANRG, in regard to the changes of pulse rate, blood pressure, in the levels of serum BUN, creatinin, sodium, total protein, and albumin before albumin infusion and 48 hours after albumin infusion, and documented and/or clinical infections after albumin infusion, hospitalization duration, the rate of exitus in hospital and overall survival. There was no difference in patient characteristics between two groups. Likewise, the groups were not different from each other in terms of the changes of puls rate, blood pressure, in the levels of serum BUN, creatinin, sodium, and documented and/or clinical infections after albumin infusion (p> 0.05). There was a significant increase in the levels of serum total protein and albumin in ARG (p< 0.05). The rate of exitus in hospital is not different between two groups. The median duration of hospitalization was longer in ANRG (p= 0.022). The overall survival was significantly better in ANRG (p= 0.018). Albumin infusion is not benefical in terminally ill hypoalbuminemic cancer patients. Furthermore, it was found that the survival was significantly worse in patients receiving albumin.
机译:在这项回顾性研究中,研究对象是白热病患者输注白蛋白是否有益。从2000年3月至2003年3月31日,回顾性分析了27例接受白蛋白输注的绝症低白蛋白血症癌症患者(白蛋白接受组-ARG)的病历。根据年龄,性别,ECOG PS,诊断和转移部位的数量,该人群与没有白蛋白输注的27名绝症患者(白蛋白未接受ANRG组)匹配(1:1)。在输注白蛋白前和输注白蛋白后48小时,将ARG与ANRG的脉搏率,血压,血清BUN,肌酐,钠,总蛋白和白蛋白水平的变化进行比较,并记录和/或临床输注白蛋白后的感染,住院时间,住院率和整体生存率。两组之间的患者特征无差异。同样,两组在输注白蛋白后的脉搏率,血压,血清BUN,肌酐,钠的含量以及有证和/或临床感染的变化方面也没有差异(p> 0.05)。 ARG的血清总蛋白和白蛋白水平显着增加(p <0.05)。两组的住院退出率无差异。 ANRG的中位住院时间更长(p = 0.022)。 ANRG的总生存期明显更好(p = 0.018)。绝症低白蛋白血症癌症患者输注白蛋白不是有益的。此外,发现接受白蛋白的患者的存活明显更差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号